帕博利珠单抗联合化疗方案——PD-L1阳性（CPS≥10）转移性及晚期三阴性乳腺癌的一线治疗方案 - Suppr

Suppr

超能文献

[Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS≥10) metastatic and advanced triple-negative breast cancer].

作者信息

Loison Rebecca, Loirat Delphine

机构信息

Institut Curie, département de radiothérapie, 92210 Saint-Cloud, France.

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

出版信息

Bull Cancer. 2022 Apr;109(4):387-389. doi: 10.1016/j.bulcan.2022.01.004. Epub 2022 Mar 4.

DOI:10.1016/j.bulcan.2022.01.004

PMID:35256159

Abstract

摘要

相似文献

[Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS≥10) metastatic and advanced triple-negative breast cancer].帕博利珠单抗联合化疗方案——PD-L1阳性（CPS≥10）转移性及晚期三阴性乳腺癌的一线治疗方案

Bull Cancer. 2022 Apr;109(4):387-389. doi: 10.1016/j.bulcan.2022.01.004. Epub 2022 Mar 4.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。

Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.帕博利珠单抗对比研究者选择化疗用于转移性三阴性乳腺癌（KEYNOTE-119）：一项随机、开放标签、III 期临床试验。

Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4.

Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.帕博利珠单抗联合化疗治疗日本三阴性乳腺癌患者：KEYNOTE-355 研究结果。

Cancer Med. 2023 May;12(9):10280-10293. doi: 10.1002/cam4.5757. Epub 2023 Mar 14.

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.帕博利珠单抗联合化疗治疗晚期三阴性乳腺癌。

N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.

[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].新药批准：帕博利珠单抗联合化疗作为晚期/转移性食管癌或HER阴性胃食管腺癌的一线治疗，其PD-L1表达且CPS≥10

Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。

Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？

J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.

Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.联合化疗与免疫疗法治疗三阴性乳腺癌

Oncology (Williston Park). 2019 Apr 15;33(4):137-40.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。

Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.

引用本文的文献

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer.一种靶向 CD276/B7-H3 的双载药抗体药物偶联物在三阴性乳腺癌中引发细胞毒性和免疫激活。

Cancer Res. 2024 Nov 15;84(22):3848-3863. doi: 10.1158/0008-5472.CAN-23-4099.

Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis.肿瘤微环境丰富了干性特征：治疗抵抗和转移的结构事件。

Mol Cancer. 2022 Dec 22;21(1):225. doi: 10.1186/s12943-022-01682-x.

High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.CHAF1A高表达水平与PD-L1表达呈正相关，并提示胃癌预后不良。

Evid Based Complement Alternat Med. 2022 Jul 19;2022:1323321. doi: 10.1155/2022/1323321. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验